2. Results
A total of 195 subjects (treatment: 98, control: 97) who received the studied medication and had confirmed efficacy endpoints were included in the FAS. Of the patients included in the FAS, 173 (88 in the treatment arm and 85 in the control arm) who completed at least 4 weeks of study without a major protocol violation were included in the PPS-Primary, and 166 (84 in the treatment arm and 82 in the control arm) who completed the study without a major protocol violation were included in the PPS-Secondary. 